Management team

Hy BioPharma Inc. has assembled a world class team that includes experienced scientists, clinicians, regulatory and business development professionals.

Michael Steinberg, MBA
CEO — Chairman and former managing director, Hy Laboratories, Israeli bio-analysis and biological service company; director of biotechnology start-up companies such as Meditor Pharmaceuticals; MBA, NYU Business School

Alfonso Tobia, Ph.D
President — Over 35 years’ experience in pharmaceutical industry; co-inventor of key hypericin patent on photodynamic therapy; contributed to numerous IND applications and over 25 NDA and ANDA submissions; involved in development of many FDA-approved and marketed products

Gad Lavie, Ph.D.
Head of Scientific Advisory Board — Head of R&D and deputy director of the Blood Center, Sheba Medical Center; holds faculty positions at New York University Medical School and at Tel Aviv University; co-inventor of several hypericin technology patents; major contributor to product development

Zadik Hazan, M.D.
VP Research — Involved in development of several medical device start-ups; co-inventor of several patents, including utilization of hypericin for treatment and prevention of IBD; studied infectious diseases at London Institute of Tropical Medicine

Bernard Cabana, Ph.D.
VP Regulatory Affairs and Clinical Pharmacology — Over 35 years’ experience in drug development and regulatory affairs; founder and director of the FDA’s Division of BioPharmaceutics; experience includes global pharmaceutical, biotechnology and clinical research service companies